Objective: The purpose of this study was to evaluate the effects of bright light therapy combined with melatonin on motor restless behaviour in dementia.

Design: Double-blind, placebo-controlled, cross-over trial consisting of four periods. One week wash-out was followed by a 2-week period of light therapy in combination with placebo or melatonin. The second wash-out period of 1 week was followed by 2 weeks of treatment (cross-over).

Setting: Twenty-four bed medium-stay psychogeriatric ward at a Dutch psychiatric teaching hospital.

Patients: Ten patients, who met the criteria for dementia (DSM-IV) and motor restless behaviour (subscale 10 of the GIP), were included. Informed consent was obtained by proxy.

Intervention: All subjects were exposed during 2x5 consecutive days for 30 minutes to 10,000 lux bright light and randomly administered 2.5 mg melatonin or placebo at 22.00 h.

Assessments: Clinical Global Impression (CGI), Dutch version of the geriatric behavioural observation scale (GIP), Social Dysfunction and Aggression Scale (SDAS) were assessed after each wash-out and treatment period. Outcome criteria were CGI, assessing motor restless behaviour, the SDAS, measuring extrovert aggression and the GIP, assessing social, psychomotor and emotional behaviour.

Results: Six demented inpatients completed the trial. Positive effects were found for the treatment combined with placebo. Patients were less restless and more co-operative. The condition with melatonin showed no additional positive effects, additionally, patients became more aggressive and showed the same or more disturbed behaviour.

Conclusions: Bright light therapy has a positive effect on motor restless behaviour. Light therapy in combination with melatonin has no positive effects. The results might be explained by a possible overshoot of chronobiological synchronisation or the timing of the melatonin intake.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1099-1166(200101)16:1<106::aid-gps288>3.0.co;2-9DOI Listing

Publication Analysis

Top Keywords

light therapy
20
motor restless
20
restless behaviour
20
bright light
16
positive effects
12
melatonin motor
8
therapy combination
8
melatonin
7
restless
6
therapy
5

Similar Publications

Forty years of seasonal affective disorder.

Psychiatr Pol

October 2024

Uniwersytet Medyczny w Poznaniu.

In 2024, we observe the fortieth anniversary of the publication, where, for the first time, the term of Seasonal Affective Disorder (SAD) was used. Presently, SAD is regarded as a special category of mood disorder. In the American Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V), the seasonality makes a specifier, "with seasonal pattern", both for recurrent depression or Major Depressive Disorder (MDD), and for Bipolar Disorder (BD).

View Article and Find Full Text PDF

Evaluation of transcriptomic changes after photobiomodulation in spinal cord injury.

Sci Rep

January 2025

Neuroscience and Ophthalmology, Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

Spinal cord injury (SCI) is a significant cause of lifelong disability, with no available disease-modifying treatments to promote neuroprotection and axon regeneration after injury. Photobiomodulation (PBM) is a promising therapy which has proven effective at restoring lost function after SCI in pre-clinical models. However, the precise mechanism of action is yet to be determined.

View Article and Find Full Text PDF

This study investigated the knowledge, attitude, and practice (KAP) of aesthetic medicine practitioners concerning laser and/or light therapy for hypertrophic scars. Conducted at Hebei Medical University Third Hospital from December 25, 2023, to January 7, 2024, the cross-sectional study utilized a self-administered questionnaire to gather socio-demographic data and KAP scores. A total of 424 valid questionnaires were collected, with 220 (52.

View Article and Find Full Text PDF

Global insight into rare disease and orphan drug definitions: a systematic literature review.

BMJ Open

January 2025

Centre for Public Health, Institute of Clinical Sciences B, Royal Victoria Hospital, Queen's University Belfast School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK.

Objectives: This study sheds light on the available global definitions, classifications, and criteria used for rare diseases (RDs), ultrarare diseases (URDs), orphan drugs (ODs) and ultraorphan drugs (UODs) and provides insights into the rationale behind these definitions.

Design: A systematic literature review was conducted to identify existing definitions and the criteria used to define RDs, ODs and their subtypes.

Data Sources: Searches were performed in the PubMed/Medline, Embase, Scopus and Web of Science (Science and Social Sciences Citation Index) databases covering articles published from 1985 to 2021.

View Article and Find Full Text PDF

Carbon-supported Fe single atom nanozymes with long-lasting ROS generation and high NIR photothermal performance for synergistic cancer therapy.

J Colloid Interface Sci

April 2025

High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, Anhui 230031, PR China; University of Science and Technology of China, Hefei, Anhui 230026, PR China. Electronic address:

Synergistic therapy combining photothermal therapy (PTT) and chemodynamic therapy (CDT) has proven to be a highly effective strategy for cancer treatment. However, PTT heavily relies on the accumulation of therapeutic agents at the tumor site. The peroxidase (POD) activity of common catalysts can be rapidly exhausted during the accumulation process, prior to laser intervention, thereby diminishing the synergistic enhancement effect of the combined therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!